Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis.
Simultaneous Inhibition of MEK and Hh Signaling Reduces Pancreatic Cancer Metastasis.
复制标题
DOI:
10.3390/cancers10110403
复制
发表时间:
2018-10-26
期刊:
影响因子:
5.2
通讯作者:
Xie J
中科院分区:
文献类型:
--
作者:
Gu D;Lin H;Zhang X;Fan Q;Chen S;Shahda S;Liu Y;Sun J;Xie J
Pancreatic cancer, mostly pancreatic ductal adenocarcinoma (PDAC), is one of the most lethal cancer types, with an estimated 44,330 death in 2018 in the US alone. While targeted therapies and immune checkpoint inhibitors have significantly improved treatment options for patients with lung cancer and renal cell carcinomas, little progress has been made in pancreatic cancer, with a dismal 5-year survival rate currently at ~8%. Upon diagnosis, the majority of pancreatic cancer cases (~80%) are already metastatic. Thus, identifying ways to reduce pancreatic cancer metastasis is an unmet medical need. Furthermore, pancreatic cancer is notorious resistant to chemotherapy. While Kirsten RAt Sarcoma virus oncogene (K-RAS) mutation is the major driver for pancreatic cancer, specific inhibition of RAS signaling has been very challenging, and combination therapy is thought to be promising. In this study, we report that combination of hedgehog (Hh) and Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase (MEK) signaling inhibitors reduces pancreatic cancer metastasis in mouse models. In mouse models of pancreatic cancer metastasis using human pancreatic cancer cells, we found that Hh target gene Gli1 is up-regulated during pancreatic cancer metastasis. Specific inhibition of smoothened signaling significantly altered the gene expression profile of the tumor microenvironment but had no significant effects on cancer metastasis. By combining Hh signaling inhibitor BMS833923 with RAS downstream MEK signaling inhibitor AZD6244, we observed reduced number of metastatic nodules in several mouse models for pancreatic cancer metastasis. These two inhibitors also decreased cell proliferation significantly and reduced CD45+ cells (particularly Ly6G+CD11b+ cells). We demonstrated that depleting Ly6G+ CD11b+ cells is sufficient to reduce cancer cell proliferation and the number of metastatic nodules. In vitro, Ly6G+ CD11b+ cells can stimulate cancer cell proliferation, and this effect is sensitive to MEK and Hh inhibition. Our studies may help design novel therapeutic strategies to mitigate pancreatic cancer metastasis.
登录
查看更多内容
DOI:
10.1158/1078-0432.ccr-12-0032
发表时间:
2013-02-01
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
Chang Z;Li Z;Wang X;Kang Y;Yuan Y;Niu J;Wang H;Chatterjee D;Fleming JB;Li M;Abbruzzese JL;Chiao PJ
通讯作者:
Chiao PJ
影响因子:
50.3
作者:
Cooke VG;LeBleu VS;Keskin D;Khan Z;O'Connell JT;Teng Y;Duncan MB;Xie L;Maeda G;Vong S;Sugimoto H;Rocha RM;Damascena A;Brentani RR;Kalluri R
通讯作者:
Kalluri R
影响因子:
21.3
作者:
Costa-Silva B;Aiello NM;Ocean AJ;Singh S;Zhang H;Thakur BK;Becker A;Hoshino A;Mark MT;Molina H;Xiang J;Zhang T;Theilen TM;García-Santos G;Williams C;Ararso Y;Huang Y;Rodrigues G;Shen TL;Labori KJ;Lothe IM;Kure EH;Hernandez J;Doussot A;Ebbesen SH;Grandgenett PM;Hollingsworth MA;Jain M;Mallya K;Batra SK;Jarnagin WR;Schwartz RE;Matei I;Peinado H;Stanger BZ;Bromberg J;Lyden D
通讯作者:
Lyden D
影响因子:
6.4
作者:
Kitadai, Yasuhiko;Sasaki, Takamitsu;Fidler, Isaiah J.
通讯作者:
Fidler, Isaiah J.
影响因子:
15.9
作者:
Leca, Julie;Martinez, Sebastien;Tomasini, Richard
通讯作者:
Tomasini, Richard